Most Read Articles
6 days ago
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

3 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Pearl Toh, 3 days ago
Drinking more water did not significantly slow down the decline in kidney function of patients with stage 3 chronic kidney disease (CKD) at 1 year compared with patients who maintained their daily water intake, the CKD WIT* randomized study suggests.

BICAMS suitable for measuring cognition during multiple sclerosis relapse

10 Jun 2018
Multiple Sclerosis (MS) is a debilitating disease, in which nerve damage affects communications between the brain and body. HSCT could provide the therapeutic answer for MS patients.

Use of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is suitable for a quick assessment of patient cognition during multiple sclerosis (MS) relapse, a recent study has shown.

The study included 120 MS patients (60 with relapsing and 30 with stable disease) and 30 healthy controls. All groups were matched according to demographic and disease characteristics.

Relapsing and stable MS patients consistently had lower mean BICAMS scores than healthy controls: Symbol Digit Modalities Test (SDMT; 40.18±11.42 and 46.60±11.54 vs 53.83±8.91; p<0.001), Brief Visuospatial Memory Test-Revised (BVMT-R; 22.57±6.07 and 25.23±5.66 vs 29.03±4.22; p<0.001) and California Verbal Learning Test, II edition (CVLT-II; 52.02±9.61 and 54.80±9.40 vs 66.97±4.68; p<0.001).

Scores during relapse and 1 and 3 months after relapse were then compared. Scores were significantly higher 1 month after relapse (SDMT: 46.20±12.28; BVMT-R: 26.30±4.56; CVLT-II: 58.45±8.36). Only scores in the CVLT-II showed further significant improvement between 1 and 3 months.

“Assessing the results after relapse, we found that the results of all of the tests were significantly higher at 1 month after relapse than during relapse and that the results of only the verbal memory test were significantly higher at 3 months after relapse than after 1 month,” said researchers.

“Neuropsychological assessment, like physical disability assessment, is important during relapse. BICAMS may be suitable for quick and effective assessment of cognition during relapse,” they added.

For the study, MS patients were eligible for inclusion if they had not been assessed with BICAMS in the past and if they were not taking medications that may affect cognition. One-way analysis of variance was used to compare the means among the three patient groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

3 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Pearl Toh, 3 days ago
Drinking more water did not significantly slow down the decline in kidney function of patients with stage 3 chronic kidney disease (CKD) at 1 year compared with patients who maintained their daily water intake, the CKD WIT* randomized study suggests.